Michael Donohue

Michael Donohue, PhD is an Associate Professor of Neurology at the University of California, San Diego (UCSD), serving as Associate Director of Biostatistics at the Alzheimer’s Therapeutic Research Institute (ATRI) and Co-Lead of the Biostatistics Unit at the Alzheimer’s Clinical Trial Consortium (ACTC). He holds a PhD in Mathematics (2005) and focuses on applying advanced statistical methods to Alzheimer’s clinical trials and observational studies, particularly leveraging the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. His work emphasizes understanding Alzheimer’s progression through biomarkers and designing innovative clinical trials to slow or prevent disease.

Educational background: PhD in Mathematics (year not specified in text).

Research interests include:

• Statistical methodologies for Alzheimer’s trials and observational studies
• Biomarker analysis (amyloid, tau, neurodegeneration)
• Clinical trial design, including outcome measure selection
• Preclinical Alzheimer’s interventions
• Biomarker validation and harmonization
• Inclusion of underrepresented populations in research

Key articles focus on:

His work spans statistical innovation in Alzheimer’s research, biomarker-driven trial design, and safety monitoring in clinical trials. Recent studies address cognitive resilience, imaging standards (e.g., CLARiTI), and plasma biomarker accuracy.

Grants and funding include support from the National Institute on Aging, Alzheimer’s Association, Michael J. Fox Foundation, and UCSD’s Clinical and Translational Research Institute.

No formal advisees are listed, though his roles in ATRI and ACTC imply collaborative research leadership. His work supports global trials like A4 and AHEAD 3-45, advancing prevention strategies for Alzheimer’s.

Labs/teams: Alzheimer’s Therapeutic Research Institute (ATRI), Alzheimer’s Clinical Trial Consortium (ACTC), and the ADNI Biostatistics Core.